Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.53 |
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.53 |
| ▸ | HRH2 | P25021 | 2/20 | 0.53 |
| ▸ | HRH1 | P35367 | 2/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | DRD1 | P21728 | 1/20 | 0.53 |
| ▸ | HTR1B | P28222 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15067221 | 0.93 | MEN1 (0.61) | KMT2AMEN1NPSR1SMN1; SMN2NPC1 | |
| SCHEMBL265902 | 0.87 | MEN1 (0.58) | KMT2AMEN1NPSR1SMN1; SMN2NPC1 | |
| SCHEMBL15499538 | 0.86 | KMT2A (0.60) | KMT2AMEN1NPSR1SMN1; SMN2NPC1 | |
| SCHEMBL324086 | 0.86 | TMEM97 (0.64) | KMT2AMEN1NPSR1SMN1; SMN2NPC1 | |
| SCHEMBL2011989 | 0.85 | MEN1 (0.60) | KMT2AMEN1NPSR1SMN1; SMN2NPC1 | |
| SCHEMBL1489028 | 0.85 | KMT2A (0.59) | KMT2AMEN1NPSR1SMN1; SMN2NPC1 | |
| SCHEMBL2440342 | 0.85 | TMEM97 (0.57) | KMT2AMEN1NPSR1SMN1; SMN2NPC1 | |
| SCHEMBL4814264 | 0.84 | MEN1 (0.76) | KMT2AMEN1NPSR1SMN1; SMN2NPC1 | |
| SCHEMBL3970912 | 0.84 | MEN1 (0.76) | KMT2AMEN1NPSR1SMN1; SMN2NPC1 | |
| SCHEMBL7393652 | 0.84 | MEN1 (0.76) | KMT2AMEN1NPSR1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 443 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431325-A | 3- (1H-pyrazol-1-yl) azetidine compound and synthetic method thereof | 诚达药业股份有限公司 | 2025-02-14 | — | — | CN | claimed |
| US-20140275527-A1 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases | EXELIXIS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| WO-2026102212-A1 | MACROCYCLIC MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| EP-4721737-A1 | USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES | Scinnohub Pharmaceutical Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-20260085064-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12570646-B2 | Compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2026-03-10 | — | — | US | disclosed |
| EP-4698517-A1 | <SUP2/>? <SUB2/>?4?NOVEL COMPOUNDS AS ?? <NS1:SUB>7</NS1:SUB>?INHIBITORS | Evotec International GmbH (DE) | 2026-02-25 | — | — | EP | disclosed |
| EP-4696692-A1 | CRYSTAL OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-02-18 | — | — | EP | disclosed |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20040072802-A1 | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | DUAN JINGWU (US) | 2004-04-15 | — | — | US | disclosed |
| EP-1263756-B1 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6495565-B2 | FOR THERAPY OF ACUTE INFECTION, ACUTE PHASE RESPONSE, AGE RELATED MACULAR DEGENERATION, ALCOHOLISM, ANOREXIA, ASTHMA, AUTOIMMUNE DISEASE, AUTOIMMUNE HEPATITIS, BECHET'S DISEASE, CACHEXIA, CALCIUM PYROPHOSPHATE DIHYDRTATE DEPOSITION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-17 | — | — | US | disclosed |
| EP-1263756-A2 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | disclosed |
| WO-2001070734-A2 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
| US-5883102-A | Pharmaceutically active compounds | ASTRA PHARMACEUTICALS LIMITED (GB) | 1999-03-16 | — | — | US | disclosed |
| WO-1992002521-A1 | 1-AZABICYCLO[3.2.0]HEPT-2-ENE-2-CARBOXYLIC ACID COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-02-20 | — | — | WO | disclosed |
| US-4088644-A | N-Acyl-3-azetidinone | SCHERING-CORPORATION (US) | 1978-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072802-A1 | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | TNF, XPNPEP1, MMP2 | KMT2A 1914/4885MEN1 2668/4885NPSR1 861/4885 |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, VHL, BAZ1A | KMT2A 928/4885MEN1 4186/4885NPSR1 4041/4885 |
| US-12570646-B2 | Compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same | HDAC6, HDAC3, HDAC1 | KMT2A 176/4885MEN1 3713/4885NPSR1 2489/4885 |
| US-20140275527-A1 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases | NRAS, BRAF, KRAS | KMT2A 1187/4885MEN1 164/4885NPSR1 4417/4885 |
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | TNF, XPNPEP1, MMP2 | KMT2A 1686/4885MEN1 2731/4885NPSR1 864/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | KMT2A 2541/4885MEN1 3186/4885NPSR1 4719/4885 |
| US-20260085064-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BCL6B | KMT2A 1335/4885MEN1 783/4885NPSR1 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.